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ORIGINAL ARTICLE
Clinical prognostic factors in pleural mesothelioma: best supportive care and
anti-tumor treatments in a real-life setting
Thomas Ringgaard Petersena,b, Vasiliki Panoua,c, Christos Meristoudisd, Ulla Møller Weinreicha,e and
Oluf Dimitri Røee,f,g,h
aDepartment of Respiratory Disease, Aalborg University Hospital, Aalborg, Denmark; bDepartment of Oncology, Regional Hospital West
Jutland, Herning, Danmark; cDepartment of Respiratory Medicine, Odense University Hospital, Odense, Denmark; dDepartment of Pathology,
Aalborg University Hospital, Aalborg, Denmark; eThe Clinical Institute, Aalborg University, Aalborg, Denmark; fDepartment of Oncology,
Clinical Cancer Research Center, Aalborg University Hospital, Aalborg, Denmark; gDepartment of Oncology, Levanger Hospital, Nord-
Trøndelag Health Trust, Levanger, Norway; hDepartment of Clinical and Molecular Medicine, Norwegian University of Science and
Technology, Trondheim, Norway
ABSTRACT
Background: This study aims to investigate patient- and disease characteristics associated with sur-
vival in malignant pleural mesothelioma (MPM) patients with anti-tumor treatment or with best sup-
portive care (BSC).
Materials and methods: Consecutive MPM cases diagnosed in North Denmark Region from 1972 to
2015 were reevaluated and verified by two pathologists using modern immunohistochemical techni-
ques. Danish registries and hospital records were used to gather patient-, asbestos exposure-, and dis-
ease information.
Results: Of the 279 patients, anti-tumor treatment was administered to 184 patients (66.0%). All of
those received chemotherapy alone or as part of a multimodal treatment, where pemetrexed was
given to 126 (68.5%) patients. Asbestos exposure was documented in 92.5% of all patients. In the
treated group, mean age was lower (66 years versus 74 years, p< 0.01), rate of occupational asbestos
exposure was higher (74.5 versus 54.7%, p< 0.01), more patients had better performance score (98.4
versus 60%, p< 0.01) and stage was lower (81 versus 63.2%, p< 0.01) compared to the BSC group.
Multivariate analysis showed that epithelioid subtype was the only common prognostic factor for OS
in both groups. In BSC patients, good PS and female gender was associated with improved OS.
Median overall survival (OS) was 17 versus 4months (p< 0.01), and independently of the histopatho-
logical subtype, the median and 2-year survival was higher in the treated versus the BSC
group (p< 0.02).
Conclusions: This retrospective study showed that epithelioid subtype is the only independent posi-
tive prognostic factor of survival in treated patients with MPM. For BSC patients, the epithelioid sub-
type, good PS, and female gender were positive prognostic factors, while age and comorbidities were
not significant. This study with long-term follow-up of treated and BSC MPM patients can contribute
to the clinical stratification of patients. Further validation is appropriate to verify these findings.
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Malignant mesothelioma (MM) is a relatively rare and often
aggressive tumor arising from mesothelial or submesothelial
cells in serosal membranes, most commonly located in the
pleura [1].
Median survival in malignant pleural mesothelioma (MPM)
patients treated by best supportive care (BSC) has been
reported in the range 2–8months, and in patients treated
with pemetrexed-platinum plus bevacizumab the median
survival is 18.8months; however, the 5-year survival is still
<5% [2,3]. Currently a combination of nivolumab and
ipilimumab has received FDA approval as first line treatment
that may change the outcomes more favorably [4].
Multimodal therapy with chemotherapy, surgery and
radiotherapy is used in a subset of patients, but even if there
are some long-term survivors, there is no definitive cure for
this disease [1].
Since the seminal paper by Wagner et al. in 1962, asbes-
tos exposure as an etiological factor for MPM has been thor-
oughly documented [1,5–7]. Asbestos was banned in several
countries in the 1980s, but due to latency of 20–70 years and
continued asbestos use in several countries the incidence
has plateaued or is increasing world-wide [1,8].
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The overall poor prognosis is linked to the biology of this
disease, its innate or acquired resistance to therapy, as well
as late diagnosis [9,10]. The histological subtypes are prog-
nostic for both response and survival. The epithelioid
(50–70% of cases) have a significantly better response and
overall survival (OS) versus sarcomatoid (7–20%) and biphasic
(20–35%) subtypes [8,11]. However, solid evidence regarding
prognostic factors of OS both in treated and BSC patients is
rather limited [11,12]. One reason for these discrepancies
may be due to the lack of data in treated and BSC patients.
Improved knowledge on prognostic factors could aid clini-
cians in stratification and more personalized approaches
to treatment.
International incidence of MPM is reported to be around
1–2 per million, but in the Region of North Denmark, the
crude incidence from 2010 to 2015 was 6.2/100,000 for men
and 1.6/100,000 for women due to a large asbestos cement
factory and shipyards that operated in the area for more
than six decades [1,13]. The MM cohort of Aalborg University
Hospital is one of the largest single-institution cohorts with
complete clinical data regarding treatment and asbestos
exposure [13].
The primary aim of this study was to investigate which
patient- or disease characteristics (i.e. age, gender, asbestos
exposure, tumor subtype, stage of disease, Eastern
Cooperative Oncology Group performance status (PS), and
comorbidities) are associated with survival in MPM patients
with or without anti-tumor treatment, and compare survival
between these two groups.
Material and methods
Study design
This retrospective study included all patients from the North
Denmark Region diagnosed with MM from 1972 to 2015.
Data outputs were originally obtained as part of an ongoing
research project on MM at Aalborg University Hospital.
Approval from the Danish Data Protection Agency and the
Ethical Committee (ID# N-20140032) was acquired. The meth-
ods regarding pathology evaluation and asbestos exposure
data have been published previously [13].
Data collection
Archival data from the Institute of Pathology, Aalborg
University Hospital, were retrieved from 1972 to 2015 and
patients were followed until September 2018. Pathology data
included diagnostic method, (cytology or histology), tumor
subtype, (epithelioid, sarcomatoid or biphasic), and certainty
of diagnosis, classified in a 5-tier scheme. All cases were re-
classified by two pathologists using modern immunohisto-
chemical panels according to the most recent International
Mesothelioma Interest Group guidelines, when tissue was
available [14]. Tiers included (1) definitely, (2) probably, (3)
likely, (4) unlikely, (5) definitely not, of which tier 4 and 5
were excluded.
Clinical and survival data concerning age time of diagno-
sis, localization, stage, treatment, and OS were obtained from
medical records and the Danish Cancer Registry. Age was
analyzed as a continuous variable. Tumor localization
was divided into pleural and non-pleural, and cases with
non-pleural location were excluded (Figure 1). Extent of dis-
ease was classified as ‘local’ or ‘metastatic’ prior to 2002 and
according to Tumor Node Metastasis (TNM) in cases after
2002. Patients were grouped as ‘early’ (TNM stage 1–3 or
‘localized’) and ‘late’ (TNM stage 4 or ‘metastatic’) stage.
Treatments were categorized as BSC, chemotherapy only,
chemotherapy and radiation, chemotherapy, and surgery and
trimodal treatment (chemotherapy, radiation, and surgery).
The OS was defined as time from diagnosis to death. Patient
PS was grouped in good (0–2) or poor (3–4). The PS and sig-
nificant comorbidities (i.e. as heart-, lung-, renal failure, vas-
cular diseases, and other cancers) were obtained from the
National Patient Registry, which is a high-quality database
established in 1977, comprising patient information regis-
tered from all hospital wards in Denmark [15]. It was not
possible to achieve PS from registries for patients diagnosed
before to 2002 but these were identified by thorough search
through hospital records. Medical records were in general
used to supplement and validate information.
Asbestos exposure type was determined from data by the
Danish Supplementary Fund Register and the Danish Civil
Registration System. Asbestos exposure was categorized in
occupational, environmental, domestic, combinations of
those and no exposure. Occupational exposure was defined
Figure 1. Flow-chart of the inclusion process of the study population.
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as asbestos-related work i.e. shipbuilding, isolation, mason,
carpenter, blacksmith, electrician, joiner, or working at
Danish Eternit Factory or Aalborg shipyard. Domestic expos-
ure was defined as sharing residence with an occupationally
exposed person. Environmental exposure was defined as liv-
ing or working within 10,000 meters from asbestos emitting
locations, based on previous studies [16]. Exposure type was
subdivided in occupational exposure (including patients with
any non-occupational exposure), non-occupational exposure
(defined as sole environmental, domestic, or mixed exposure
with no occupational component), and no exposure.
Statistical methods
Normal distribution was evaluated with Q-Q plots.
Descriptive statistics and Fisher’s exact tests were used to
evaluate the population characteristics. Univariate cox regres-
sion analysis was used to determine which independent vari-
ables correlated with OS. Variables with p<0.10 were
considered significant, and included in a multivariate Cox
regression analysis, used to determine independent signifi-
cance, in which p<0.05 was considered significant. Kaplan
Meier estimate and log rank test were used to investigate
survival differences in subtypes among treated and BSC
groups. Statistical analysis was performed using SPSS
Statistics software version 25.
Results
Study population
Of 568 patients with a MM diagnosis, 279 with verified MPM
were eligible for inclusion in the study (Figure 1). At the time
of data collection, 10 patients were alive.
A documented asbestos exposure was established in 258
patients (92.5%), the majority with occupational asbestos
exposure (n¼189, 67.7%) (Table 1). The majority of the
patients had TNM stage III or IV, good PS, epithelioid subtype
and diagnosis was mostly confirmed by histological diagnos-
tic methods (Table 1). Ischemic heart disease was the most
frequent significant comorbidity (n¼47, 15.7%). In the treated
group, mean age was lower (66 versus 74 years, p<0.01), rate
of occupational asbestos exposure was higher (74.5 versus
54.7%, p<0.01), more patients had better performance score
(PS, 98.4 versus 60%, p<0.01) and stage was lower (81 versus
63.2%, p<0.01) compared to the BSC group. There was no
difference between the groups regarding comorbidities or
histological subtypes. Anti-tumor treatment was given to 184
patients (66.0%) where all received chemotherapy alone or
as part of multimodal treatment (Table 1). Pemetrexed-based
(pemetrexed alone or combined with platinum) chemother-
apy was given to 126 (68.5%) patients. Median overall sur-
vival (OS) was 17 versus 4months, p<0.01) in the treated
versus the BSC group.
Prognostic factors for survival
The univariate analyses showed that favorable factors for OS
in the BSC group were female gender, epithelioid subtype,
early stage, and good PS, while in the treated group only
epithelioid subtype was favorable. As no other factors had
univariate correlation (p<0.1) in treated patients, no multi-
variate analysis was made in this group. However, even
when adjusting for factors with p<0.2 (age, stage, and
comorbidities), subtype remained the only significant vari-
able (p<0.019) (Table 2). As there were only three patients
with poor PS in the treated group, this variable was not
included in Cox regression analysis. Multivariate analysis in
the BSC group revealed female gender, epithelioid subtype,
and good PS were associated with higher OS (Table 2.
Independently of the histopathological subtype, the median
and 2-year survival were higher in the treated versus the BSC
group (p<0.02) (Table 2, Figure 2).
Median survival for patients with epithelioid and non-
epithelioid subtypes in the BSC groups were five and two
months (p<0.001), respectively. For treated patients with





Age, mean (SD) 74.18 (8.9) 65.75 (8.6) <0.01
Survival months, median (IQR) 4.0 (7.0) 17.0 (14.75) <0.01
Gender, male, N (%) 66 (69.5) 157 (85.3) <0.01
Asbestos exposure
N (%)
Occupational 52 (54.7) 137 (74.5) <0.01
Non-occupational 29 (30.5) 40 (21.7)




0 4 (4.2) 73 (39.7) <0.01
1 31 (32.6) 92 (50.0)
2 22 (23.2) 16 (8.7)
Poor
3 21 (22.1) 3 (1.6)
4 17 (17.9) 0
Comorbidities, yes, N (%) 51 (53.7) 84 (45.7) 0.21
Subtype N (%)
Epithelioid
Epithelioid 61 (64.2) 105 (57.1) 0.30
Non-epithelioid
Biphasic 16 (16.8) 67 (36.4)




TNM I 3 (3.2) 22 (12.0) <0.01
TNM II 13 (13.7) 41 (22.3)
TNM III 18 (18.9) 65 (35.3)
Local 13 (13.7) 7 (3.8)
Regional spread 13 (13.7) 14 (7.6)
Late
TNM IV 32 (33.7) 35 (19.0)
Metastatic 3 (3.2) 0
Treatment
N (%)
Chemotherapy 0 94 (51.1) NA
Chemotherapyþ Radiation 0 46 (25.0)
Chemotherapyþ Surgery 0 20 (10.9)
Chemotherapyþ Radiationþ Surgery 0 24 (13.0)
p Value <0.05 indicates significant difference between the BSC and treated
group. BSC: best supportive care; SD: standard deviation; IQR: inter quartile
range; PS: performance status; HR: hazard ratio; NA: not applicable; TNM:
tumor node metastasis.
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epithelioid and non-epithelioid subtypes the median survival
was 18 and 17months (p<0.02), respectively.
The 2-year survival in the BSC group was 1.6% for epithe-
lioid and 0% for non-epithelioid subtypes. Epithelioid sub-
types receiving treatment had a 2-year survival of 33.3%
(n¼35), while it was 24.0% (n¼19) for non-epithelioid sub-
types (p<0.05).
Discussion
Prognostic information may help in stratification of MPM
treatment. This retrospective study reiterated that epithelioid
subtype is the most important independent prognostic factor
of survival in patients with anti-tumor treatment, but age,
stage and female gender were not significant. In the BSC
patients, the epithelioid subtype, good PS, and female
gender were positive prognostic factors, while age and
comorbidities were not associated with OS in either group.
Prognostic factors of survival
Prior literature on prognostic factors of MPM often analyze
treated patients alone or pool them with untreated patients.
In this study, the patients in the BSC group consisted of
patients from the era prior to active treatment (1972–2000)
as well as patients that were not regarded as fit for treat-
ment from the era of active treatment. This relatively large
cohort of untreated patients made it possible to assess differ-
ences in prognostic factors among the treated and the BSC
groups separately.
Epithelioid tumors were found to be independently asso-
ciated with better OS than non-epithelioid, both in the
Table 2. Uni- and multivariate analyses.
BSC group Treated group
Univariate Multivariate Univariate
HR 95% CI p-Value HR 95% CI p-Value HR 95% CI p-Value
Age, years 0.99 0.97–1.02 0.56 NA 1.01 0.99–1.03 0.16
Gender, male 1.64 1.04–2.58 0.03 1.56 0.99–2.47 0.05 1.17 0.77–1.80 0.46
Occupational exposure 1.05 0.58–1.90 0.88 NA 0.87 0.41–1.87 0.73
Non-occupational exposure 0.81 0.43–1.55 0.53 NA 0.66 0.29–1.49 0.32
Subtype, epithelioid 0.52 0.34–0.81 <0.01 0.47 0.30–0.74 <0.01 0.7 0.52-0.96 0.02
Stage, early 0.68 0.44–1.04 0.08 0.73 0.47–1.13 0.16 0.78 0.54–1.30 0.19
PS, good 0.59 0.39–0.90 0.03 0.58 0.37–0.90 0.02 NA
Significant comorbidity 1.18 0.78–1.78 0.43 NA 1.27 0.94–1.71 0.12
Variables with p values >0.1 in the univariate analyses were included in the multivariate analysis where p<0.05 indicates significant correlation. The PS was not
analyzed in the treated group due to small number of patients with PS >2.A Cox regression analysis on age, gender, stage, comorbidities and subtype in the treated group correcting for the other variables and again, only subtype
was significant (p¼0.019). BSC: best supportive care; CI: confidence interval; NA: not applicable; PS: performance status; HR: hazard ratio.
Figure 2. Kaplan–Meier survival curves according to MPM subtypes for the BSC and treated group. Dotted lines indicate BSC group and full lines indicate treated
group. p Value <0.05 (log-rank test) indicates significant difference in survival between MM subtypes within the groups. BSC: best supportive care; OS: over-
all survival.
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patients that received active treatment and in the BSC group.
These findings support results of prior studies suggesting
that sarcomatoid and biphasic tumors are more aggressive
and more resistant, with lower OS, regardless of treatment
[11,12,17–20]. However, any type of treatment seemed to
have a positive impact on OS versus the BSC group.
Interestingly, patients with the non-epithelioid subtype had a
median survival of 17months in contrast to the epithelioid in
the BSC group that had five months median OS, indicating a
good effect of treatment also in this unfavorable subgroup.
All treated patients received some form of chemotherapy
but only a minor subgroup received chemotherapy plus sur-
gery or tri-modal treatment. The survival difference between
treated and untreated is more than one year, and this may
reflect the positive effect of treatment. However, there was
also a significantly higher number of patients with PS 3–4
and more advanced disease in the BSC group. So, the true
difference and impact of treatment is probably more modest.
Good PS (PS 0–2) was independent positive factor of OS
in BSC patients. Patients with poor PS are immobilized and
affected by symptoms, hence more unlikely to receive treat-
ment according to modern treatment indications [21]. This
further explains why very few patients in the treated group
had poor PS. One study did not find a significant influence
of PS on OS, however, that study pooled BSC and treated
patients, and split groups into PS¼0 and PS¼1–5, hence
potentially confounding the poor PS group with patients
with relatively good clinical status 11. Three other studies
that differentiated groups similar to this one found signifi-
cant impact of good PS on OS [17,20,22]. Our findings con-
firm that PS is important for OS as part of the natural history
of the disease [17,20,22].
Female gender was a significant favorable factor in BSC
patients. While no significance was found in the treated
group, only 14.7% were women, hence they were potentially
underrepresented. Some previous studies have suggested
that female gender is associated with improved OS in MM
patients, while others did not [11,12,23]. This study indicates
that female gender is a significant protective factor in BSC
patients, although the mechanisms responsible for this are
unclear [24].
Early stage appeared to be positive prognostic for OS in
BSC patients, as expected. When adjusted to subtype and PS,
it was no longer a significant factor, indicating that the non-
epithelioid subtype and PS probably overshadows the prog-
nostic effect of stage. Tumor stage was not a significant fac-
tor in the treated patients. In the treated group, late stage
disease comprised only 19%, hence potentially underrepre-
sented. However, the high rate of non-epithelioid type (46%)
may confound the outcome. Prior literature, where both
treated and BSC groups were pooled, have found contradict-
ing results [12,19]. Advanced tumor stage may not be as
important for prognosis if a patient has a good PS and
responds to chemotherapy. There are, however, several ques-
tions regarding staging. In MPM, staging is difficult due to
several challenges, such as the radiological evaluation of
tumor burden in pleura and lymph nodes [25]. Death from
mesothelioma is often unrelated to tumor burden, even
locally advanced tumors can be lethal [26]. Moreover, the
staging system has evolved over the last decades and it is
difficult to compare staging in 1990 and 2015. Therefore, the
staging information in this population spanning over 40 years
may not be that reliable.
There is limited literature investigating significant comor-
bidities as a prognostic factor. Comorbidities can theoretic-
ally alter the clinical progress with potential limitations to
treatment options and ultimately lead to death. However,
this study found no independent effect of comorbidities on
OS in neither BSC nor treated patients. A potential explan-
ation is that quantitative data on comorbidity does not detail
how or if a patient is clinically affected. Hence, some comor-
bidities may be correlated with PS, while asymptomatic
comorbidities may not alter the clinical process significantly.
However, the accuracy of the comorbidity data may be ham-
pered by the retrospective nature of the study.
Age was not a significant prognostic factor in either
group. Other studies found that age was a significant factor
[11,23]. However, they did not adjust for PS, and PS does not
necessarily to correlate to age, as seen in other patient pop-
ulations with cancer [27]. While this study did find a higher
mean age in the BSC group, low age did not seem to predict
a better OS, regardless of treatment, after adjustment to
important patient and disease characteristics.
Asbestos exposure had no correlation with OS after multi-
variate adjustment, as has been already by suggested by
other studies [11,17,18,20]. Domestic exposures for men were
only available after 2001, and considering three male
patients were registered with no exposure prior to this, they
may potentially have been exposed non-occupationally.
However, our study had uniquely detailed data regarding
occupation, household, and addresses for the sample popu-
lation. This provided a more reliable analysis of asbestos
exposure types compared to other studies, and potential
low-scale misclassification would not alter the conclusions.
Interestingly there were significantly more patients with
occupational exposure in the treated group. This may be
due to the fact that individuals that have been exposed
knowingly will be more alert if they get symptoms and seek
medical attention while they are in good PS, and therefore
be fit to receive treatment.
Study population characterization
This study found that 92.5% of the MPM patients had been
exposed to asbestos, which is much higher than studies
from other countries, while similar to other Danish studies
[17–20]. Potential reasons are that most studies defined
asbestos exposure as prior occupation with asbestos mater-
ial, hence excluding non-occupational exposure. Further,
information needed to classify exposure type (i.e. household,
address, and occupational history) are uniquely and readily
accessible in the high quality The Supplementary Fund
Register and the Civil Registration System databases for each
Danish citizen [28,29]. This study suggests that environmen-
tal asbestos plays an even more prominent role in MPM than
originally thought.
ACTA ONCOLOGICA 525
Mean age and median OS were very similar to demo-
graphics of other countries, further validating that prognosis
for MPM patients is poor [11,12,17–19]. In the literature,
median OS for all included patients ranges from 10 to
15months, which corresponds to our findings
[11,12,17–20,30]. Two studies reported OS in BSC and treated
groups [20,30]. Both report higher OS for BSC patients (7.0
and 8.0months), and lower OS for treated patients (11.0 and
11.5months) compared to this study. The reason could be
due to differences in patient selection and treatments avail-
able at a certain time point [20,30]. Epithelioid subtype was
the most frequent histopathological subtype, followed by
biphasic and sarcomatoid, respectively. Frequencies of epi-
thelioid subtypes are consistent with the literature from
other countries, however, distribution of biphasic and sarco-
matoid subtypes are more diverse. One reason could be that
the diagnosis relies on a semiquantitative method of estimat-
ing sarcomatoid components [14]. Regarding stage of dis-
ease, TNM stage III and IV were the most common,
recapitulating the results of four other studies [11,12,17,19].
The strengths of this study is the long period over where
this material has been collected, the completeness of the
material, the relatively large group of non-treated cases, the
comprehensive reevaluation of histology, the detailed clinical
data on asbestos exposure and outcomes. The main limita-
tions are the retrospective design and the lack of response-
data. Further investigation into the treatment details regard-
ing chemotherapy type, number of cycles etc. could add to
the quality of results. Our data show that the characteristics
of Danish MPM patients are similar with those reported in
other countries, although asbestos exposure was more preva-
lent, probably due to the access to complete and
detailed databases.
Conclusions
This retrospective study reiterate that the epithelioid subtype
is a strong independent prognostic factor both in BSC and
treated MPM patients, while age and comorbidities do not
seem to be significant factors. Patients with non-epithelioid
MPM treated with anti-neoplastic treatment had significantly
better survival than BSC patients of any subtype, which rein-
forces the rationale to treat this patient group. Among BSC
patients, the epithelioid subtype, good PS, and female gen-
der were positive prognostic factors but all patients with BSC
had a very low life expectancy. This long-term study can con-
tribute to the clinical stratification of MPM patients and valid-
ation in other cohorts is appropriate to verify these findings.
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